Our guest, Hunter Ziesing shares his work with AI in assisting individuals in their quest for health and longevity.
Hunter spent the bulk of his career in investment banking focusing on the Healthcare, Consumer, and Technology areas. He was the founder of Charity of Choice, a non-profit focused on cancer research and health prevention.
Early Overall Outcomes
-
Biomarker Improvements
A majority of patients showed significant movement in at least one critical biomarker (ApoB, VAT, bone density, VO2Max, HbA1c). -
~80% improved at least one key biomarker.
-
Common improvements included reductions in ApoB, decreases in visceral fat (VAT), and gains in lean mass/bone density.
-
Major Findings from Diagnostics
-
~65% of patients had at least one significant finding from testing (e.g., early CAD on Cleerly, sleep apnea, insulin resistance, GI imbalances).
-
These findings directly shaped interventions and escalations in care.
-
Symptom Reversals
-
~30% experienced meaningful reversal of previously severe symptoms (e.g., hypertension control, prediabetes reversal, improved sleep apnea, reduction in chronic GI symptoms).
Resources:
Our Sponsor:
Haven Medical maker of the Cox 8 Table